We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+57.57%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$185M
Cap. Flow
+$89.7M
Cap. Flow %
25.48%
Top 10 Hldgs %
96.59%
Holding
17
New
4
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$37.5M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$31.1M
3
TARA icon
Protara Therapeutics
TARA
+$20.3M
4
EVAR
Lombard Medical, Inc.
EVAR
+$793K
5
ZLCS
ZALICUS INC COM NEW
ZLCS
+$44K

Top Sells

Rank Stock Value
1
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$56K

Sector Composition

Rank Sector Weight
1 Healthcare 47.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNA
1
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$117M 33.09%
6,213,924
– –
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$50M 14.19%
+1,301,413
New +$31.1M
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$36.9M 10.47%
+219,901
New +$37.5M
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$26.4M 7.49%
930,682
– –
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.59B
$23.9M 6.8%
2,879,328
– –
EVAR
6
DELISTED
Lombard Medical, Inc.
EVAR
$22.1M 6.26%
3,473,452
+120,908
+4% +$793K
TARA icon
7
Protara Therapeutics
TARA
$220M
$20.3M 5.78%
+50,447
New +$20.3M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$19.4M 5.52%
1,182,196
– –
CEMP
9
DELISTED
Cempra, Inc.
CEMP
$16.8M 4.77%
714,285
– –
AMRN
10
Amarin Corp
AMRN
$299M
$7.85M 2.23%
404,374
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$5.25M 1.49%
2,728
– –
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$3.18M 0.9%
291,902
– –
HPTX
13
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.5M 0.43%
62,500
– –
ACHV icon
14
Achieve Life Sciences
ACHV
$659M
$1.35M 0.38%
274
– –
ANTH
15
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$679K 0.19%
54,749
– –
ZLCS
16
DELISTED
ZALICUS INC COM NEW
ZLCS
$44K 0.01%
+7,896
New +$44K
EPRS
17
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
– –
-7,896
Closed -$56K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2014 Portfolio in Review

As of Q4 2014, Abingworth held 17 positions worth $352M, up 111% from $167M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Abingworth deployed $89.7M of net new capital in Q4 2014, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Sientra, Inc.: 219,901 shares worth $36.9M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 29% a quarter earlier.

On the sell side, the most notable exit was EPIRUS BIOPHARMACEUTICALS INC COM, an estimated $56K sold.

  • Abingworth's largest Q4 2014 buy was Sientra, Inc.: 219,901 shares worth $36.9M.
  • Abingworth added most to Lombard Medical, Inc. in Q4 2014, an estimated $793K increase.
  • Abingworth fully exited EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014, selling an estimated $56K.
  • Abingworth's ten largest holdings make up 97% of its $352M portfolio in Q4 2014.
  • Abingworth opened 4 new positions and closed 1 in Q4 2014.
  • Abingworth's portfolio value rose 111% quarter-over-quarter to $352M.

Based on Abingworth's 13F filing for Q4 2014, filed 13 Feb 2015.